Navigation Links
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study

ussions regarding potential new indications or labelling for Diovan or Co-Diovan, or regarding potential future sales of these products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results with Diovan or Co-Diovan to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Diovan or Co-Diovan will be approved for any additional indications or labelling in any other market. Nor can there be any guarantee regarding potential future sales of Diovan or Co-Diovan. In particular, management's expectations regarding these products could be affected by, among other things, competition in general; industry, government, and general public pricing pressures; unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events, or otherwise.






Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
2. Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
9. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Post Your Comments:
(Date:7/30/2014)... , July 30, 2014   Unique ... Groups Inc.: OTC Pink: UPZS), a Delaware Corporation, ... distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a nature-based ... According to the agreement, US-based Larasan will work ... 6" frozen pizza through Larasan,s vast distribution network ...
(Date:7/30/2014)... SANTA CLARA, Calif. , July 30, 2014 /PRNewswire/ ... innovation economy, released a study today that ... venture-backed biopharma and medical device companies.  According to the ... healthcare saw the biggest potential returns since SVB started ... the year of the IPO.  Built on solid healthcare ...
(Date:7/30/2014)... 30, 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... a prominent international research and development foundation. ... innovative research-based initiatives, including those addressing health issues. ... the delivery of naloxone that could widely expand ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... This is your last week to pre-register for MD&M ... of Suppliers ,   Educational Opportunities ... all in   One Convenient Location.     ... at   http://www.MDMEast.com . Medical ...
... May 18, 2012 /PRNewswire-iReach/ -- Denton Vacuum ... today launched a new website that guides ... "The site,s organization and navigation mirror what it,s like ... and understands your business and technical drivers," says Rod ...
Cached Medicine Technology:Medical Device Developers - Network at MD&M East Next Week 2Medical Device Developers - Network at MD&M East Next Week 3Denton Vacuum's New Website Organizes Thin-Film Technology Information By Industry 2
(Date:7/30/2014)... 30, 2014 2014 Deep ... Industry” is a professional and in-depth research ... report provides basic Chitosan information, including Chitosan ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The report ... Others), by Application (Healthcare, Food, Water Treatment, Pulp & ... & ROW) - Global Trends & Forecasts to 2018". ... size of 229.54 kilotons by 2019, signifying a robust ... study. , Browse 83 market data tables and 33 ...
(Date:7/30/2014)... By Amy Norton ... -- Spending time in a garden might help soothe the ... suggests. Looking at 17 past studies, British researchers found ... garden can help soothe some dementia patients, anxiety. The ... patients are a tough subject to study -- and the ...
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for supremacy ... be those that can proliferate the fastest, researchers at ... an advance online publication of the journal Nature ... treatment of cancer with precision medicines, the study authors ... truly driving the tumor,s growth and metastasis and select ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 According ... and Machine Vision Market by Technology (ICS, MES, ... Embedded), Components (Camera, FGOL), Application (Process, Discrete) - ... published by MarketsandMarkets, the Mexican market is expected ... 6.18% by 2020. , Browse 70 market data ...
Breaking Medicine News(10 mins):Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 2Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 3Health News:Chitosan Market & Sialic Acid Industry Research Analysis for World, China Regions Available at DeepResearchReports.com 4Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 2Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 3Health News:Peracetic Acid Market Worth $664.24 Million by 2018 – New Report by MarketsandMarkets 4Health News:Gardens a Center of Calm for People With Dementia 2Health News:Gardens a Center of Calm for People With Dementia 3Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4
... tool powered by SNAPforSeniors(R) helps members quickly,locate safe housing, ... rash of tornadoes in more than 20 years destroyed ... Tennessee Tuesday night., Emergency warnings gave most residents ... housing, natural disasters bring extra fears. Lack,of mobility, limited ...
... safety review , , FRIDAY, Feb. 8 (HealthDay News) -- ... and severe side effects for others treated for a ... related products. , Most of the children were being ... caused by cerebral palsy, the U.S. Food and Drug ...
... patients (both children and adults) when given gadolinium ... pre-medicated with corticosteroids and antihistamines, according to a ... of Michigan Health Systems in Ann Arbor. ... who have a history of prior allergic-like reaction ...
... Technologically advanced program provides new treatment options for ... patients and physicians throughout the region, WAUKESHA, Wis., Feb. ... opening of its new Center for Advanced Wound,Healing. The hospital ... interested in touring the facility on Wednesday, February 13,from 4:00 ...
... The Integrated,Healthcare Association (IHA) welcomes Leah Binder, ... National Pay for Performance Summit at the,Beverly Hilton ... the,leading forum on pay for performance to enhance ... has made outstanding contributions toward the,improvement of healthcare ...
... the only one if its kind in the Pacific ... Care Alliance (SCCA),and Northwest Hospital & Medical Center today ... the development of a new, state-of-the-art,cancer treatment facility offering ... intention to develop a proton-therapy,facility in September 2006 and ...
Cached Medicine News:Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 2Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 3Health News:FDA Warns of Children's Deaths Linked to Botox 2Health News:FDA Warns of Children's Deaths Linked to Botox 3Health News:Allergic-like reactions occur in premedicated patients 2Health News:LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing 2Health News:Integrated Healthcare Association Welcomes Leah Binder, New CEO of Leapfrog Group to National Pay for Performance Summit 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 3
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
Rad-9™...
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Medicals ONE™ technology is the ... uses a patented digital sensor ... an analog sensor. Dolphin ONE™ ... the signal in the sensor, ...
Medicine Products: